Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy

‘Wave 1’ Drug Part Of Orexin Agonist Portfolio

 
• By Mandy Jackson

The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth. 

Waves crashing against the shoreline at sunset along the Western coast of Oahu
Takeda's TAK-994 could be its first Wave 1 R&D program to crash • Source: Alamy

More from Clinical Trials

More from R&D